Clinical Report: FDA Monthly Preview: Key June Decisions to Watch
Overview
The FDA has set target action dates for several investigational therapies in June 2026, including ensitrelvir for COVID-19 prophylaxis and tebipenem HBr for complicated urinary tract infections. Other notable therapies include cytisinicline for nicotine dependence and olezarsen for severe hypertriglyceridemia.
Background
The FDA's decisions on investigational therapies are crucial for advancing treatment options across various medical fields.
Data Highlights
Drug
Indication
PDUFA Date
Key Findings
Ensitrelvir
COVID-19 Prophylaxis
June 16, 2026
67% reduction in symptomatic infections
Tebipenem HBr
Complicated UTI
June 18, 2026
Noninferiority to imipenem-cilastatin
Cytisinicline
Smoking Cessation
June 20, 2026
No new safety signals
Olezarsen
Severe Hypertriglyceridemia
June 30, 2026
Up to 72% triglyceride reduction
Veligrotug
Thyroid Eye Disease
June 30, 2026
Met primary and secondary endpoints
Key Findings
Ensitrelvir reduced symptomatic COVID-19 infections by 67% in the SCORPIO-PEP trial.
Tebipenem HBr showed noninferiority to intravenous imipenem-cilastatin in the PIVOT-PO trial.
Cytisinicline demonstrated no new safety signals in the ORCA-OL safety study.
Olezarsen achieved up to 72% reduction in triglycerides in the CORE and CORE2 studies.
Veligrotug met primary and secondary endpoints in phase III trials for thyroid eye disease.
Clinical Implications
The upcoming FDA decisions may provide new treatment options for conditions such as COVID-19, complicated urinary tract infections, and severe hypertriglyceridemia.
Conclusion
The FDA's June 2026 target action dates highlight investigational therapies across multiple specialties.
Study found species-specific differences in biofilm -forming capacity and antimicrobial susceptibility among supragingival bacterial isolates from patients with active dental caries.
